NasdaqGS - Nasdaq Real Time Price • USD
Amgen Inc. (AMGN)
As of 2:39 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 20 | 27 | 26 |
| Avg. Estimate | 3.87 | 4.98 | 19.48 | 21 |
| Low Estimate | 3.32 | 4.67 | 18.85 | 18.6 |
| High Estimate | 4.87 | 5.62 | 20.47 | 23.04 |
| Year Ago EPS | 3.98 | 5 | 18.65 | 19.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 18 | 28 | 27 |
| Avg. Estimate | 7.44B | 8.29B | 32.95B | 34.11B |
| Low Estimate | 7.3B | 8.1B | 32.32B | 32.53B |
| High Estimate | 7.67B | 8.44B | 33.45B | 36.93B |
| Year Ago Sales | 6.11B | 6.99B | 28.19B | 32.95B |
| Sales Growth (year/est) | 21.90% | 18.70% | 16.90% | 3.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 3.85 | 4.49 | 4.67 | 4.6 |
| EPS Actual | 3.98 | 5 | 4.96 | 4.71 |
| Difference | 0.13 | 0.51 | 0.29 | 0.11 |
| Surprise % | 3.40% | 11.40% | 6.20% | 2.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 3.87 | 4.98 | 19.48 | 21 |
| 7 Days Ago | 3.88 | 4.97 | 19.55 | 21.06 |
| 30 Days Ago | 3.99 | 4.99 | 19.58 | 21.11 |
| 60 Days Ago | 3.68 | 4.6 | 18.07 | 19.54 |
| 90 Days Ago | 4.42 | 5.18 | 20.05 | 21.52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | 5 | 4 | 5 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 2 | 4 | 3 |
Growth Estimates
| CURRENCY IN USD | AMGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -2.80% | -- | -- | 0.30% |
| Next Qtr. | -0.40% | -- | -- | 9.80% |
| Current Year | 4.50% | -- | -- | 4.50% |
| Next Year | 7.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 5.24% | -- | -- | 11.06% |
| Past 5 Years (per annum) | 5.71% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | UBS: Neutral to Neutral | 4/17/2024 |
| Maintains | TD Cowen: Buy to Buy | 4/17/2024 |
| Reiterates | Truist Securities: Buy to Buy | 4/12/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 4/3/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 2/8/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/7/2024 |
Related Tickers
MRK Merck & Co., Inc.
127.37
+0.39%
ABBV AbbVie Inc.
168.01
-0.90%
GILD Gilead Sciences, Inc.
66.89
-0.22%
BMY Bristol-Myers Squibb Company
48.97
-0.04%
BIIB Biogen Inc.
200.09
+3.58%
LLY Eli Lilly and Company
734.11
-1.55%
JNJ Johnson & Johnson
148.54
-0.68%
AZN AstraZeneca PLC
71.14
+0.40%
NVS Novartis AG
98.20
+0.95%
GSK GSK plc
40.83
-1.01%